诺泰生物: 诺泰生物：关于实施其他风险警示暨停牌的公告

Core Viewpoint - The company, Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd., is facing a risk warning and stock suspension due to receiving an administrative penalty notice from the China Securities Regulatory Commission (CSRC) regarding false financial disclosures [1][2][3] Stock Suspension and Risk Warning - The company's stock will be suspended from trading on July 21, 2025, and will resume trading on July 22, 2025, under the new name "ST Nuotai" [2][3] - The stock code remains "688076," and the risk warning will be effective from July 22, 2025 [2][3] Reasons for Risk Warning - The CSRC's notice indicates that the company's annual report contained false financial indicators, including revenue, total profit, and net profit, but did not meet the criteria for more severe penalties [3][4] Trading Restrictions - During the risk warning period, investors are limited to purchasing a maximum of 500,000 shares of the company's stock through various trading methods [4] - The stock's price fluctuation limit remains at 20% [3][4] Company's Response and Future Actions - The company plans to take measures to mitigate the impact of the risk warning and aims to apply for the removal of the warning once certain conditions are met, including a 12-month period since the CSRC's administrative penalty decision [5] - The company emphasizes its commitment to focusing on its core business and improving compliance with regulations to protect shareholder interests [5][6] Investor Communication - The company will continue to accept investor inquiries through its hotline and the Shanghai Stock Exchange's interactive platform during the risk warning period [6]